Drug Profile


Latest Information Update: 17 Apr 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rega Institute for Medical Research
  • Developer Nonindustrial source; Rega Institute for Medical Research
  • Class Antivirals; Purines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Cytomegalovirus infections; Epstein-Barr virus infections; Hepatitis B; HIV infections

Most Recent Events

  • 31 Jul 2000 Profile reviewed but no significant changes made
  • 30 Mar 1997 Preclinical development for Cancer in Czech Republic (Unknown route)
  • 12 Aug 1996 Preclinical development for Cytomegalovirus infections in Belgium (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top